Overview
TRDA market data
Price History
TRDA price chart · 1M
- O
- 7.04
- H
- 7.36
- L
- 7.03
- C
- 7.25
- Vol
- 25,883.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $7.04
- Previous Close
- $7.04
- Day High
- $7.36
- Day Low
- $7.03
- 52 Week High
- $16.43
- 52 Week Low
- $5.65
- 7 Day Return
- -4.48%
- 30 Day Return
- +24.14%
- 90 Day Return
- +2.84%
- 1 Year Return
- -43.03%
- Daily Notional Volume
- $187.7K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.47 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.26 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,537.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $5.02 – $16.45 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $290.1M · P/B 1.28 · P/S 61.90.
Company News
Entrada Therapeutics Q2 EPS $(1.01) Beats $(1.09) Estimate, Sales $898.000K Beat $411.429K EstimateBenzinga · Aug 5, 2026, 11:34 AM
8-K filing — Entrada Therapeutics, Inc. (TRDA)SEC EDGAR · Aug 5, 2026, 11:04 AM
Guggenheim Maintains Buy on Entrada Therapeutics, Lowers Price Target to $17Benzinga · Jun 8, 2026, 2:25 PM
Entrada Advances Duchenne Muscular Dystrophy Drug to Higher Dose Cohort, Safety Review Clears Next Stage of Clinical TrialBenzinga · Jun 2, 2026, 11:17 AM
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyGlobenewswire Inc · Jun 2, 2026, 11:15 AM